Plasmatic cystatin C for the estimation of glomerular filtration rate in intensive care units

Delanaye, Pierre; Lambermont, Bernard; Chapelle, Jean-Paul; Gielen, Jacques; Gérard, Paul; Rorive, Georges

doi:10.1007/s00134-004-2189-5

Cited by 83 publications

(57 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our results were in accordance with Soni SS et al [17], Nguyen MT et al [18] and Delanaye P et al [19] who reported nearly similar results [17][18][19].…”

Section: Discussionsupporting

confidence: 92%

Early Predictors of Acute Kidney Injury (AKI) in a Sample of Egyptian Full Term Neonates

El-Gamasy¹

2017

Med Clin Rev

View full text Add to dashboard Cite

show abstract

“…Our results were in accordance with Soni SS et al [17], Nguyen MT et al [18] and Delanaye P et al [19] who reported nearly similar results [17][18][19].…”

Section: Discussionsupporting

confidence: 92%

Early Predictors of Acute Kidney Injury (AKI) in a Sample of Egyptian Full Term Neonates

El-Gamasy¹

2017

Med Clin Rev

View full text Add to dashboard Cite

show abstract

“…Multiple studies evaluating serum cystatin C (SCysC) as a GFR marker have shown that it performs at least as well as SCr in the population at large, and it is superior to SCr in specific patient populations (14). SCysC has also been proposed as an early biomarker of AKI in the intensive care (15,16), cardiac surgery (17), and radiocontrast administration (18) settings.…”

Section: T He Incidence Of Acute Kidney Injury (Aki) Is Increasingmentioning

confidence: 99%

Cystatin C as a Marker of Acute Kidney Injury in the Emergency Department

Soto

Coelho

Rodrigues

et al. 2010

Clinical Journal of the American Society of Nephrology

106

View full text Add to dashboard Cite

Background and objectives: The diagnosis of acute kidney injury (AKI) is usually based on changes in serum creatinine, which is a poor marker of early renal dysfunction. The discriminative and predictive abilities of serum and urinary cystatin C were examined for the prediction of AKI.Design, setting, participants, & measurements: In this prospective cohort study, serum and urinary cystatin C were serially measured in a heterogeneous group of patients (n ‫؍‬ 616) presenting to a tertiary care emergency department. The primary outcome was AKI, classified according to RIFLE and AKIN criteria. The secondary outcome was an adjudication based on clinical criteria to AKI, prerenal azotemia, chronic kidney disease (CKD), and normal kidney function.Results: Patients were adjudicated to have AKI in 21.1%, prerenal azotemia in 25.8%, CKD in 2.4%, and normal kidney function in 50.7%. For the diagnosis of AKI, the discriminatory ability of urinary creatinine and cystatin C was marginal. Both serum cystatin C and serum creatinine (at presentation and 6 hours later) showed high discriminatory ability for the diagnosis of AKI. However, only serum cystatin C attained a significant early predictive power (Hosmer-Lemeshow P value > 0.05). Serum cystatin C could differentiate between AKI and prerenal azotemia, but not between AKI and CKD.Conclusions: Serum cystatin C is an early, predictive biomarker of AKI, which outperforms serum creatinine in the heterogeneous emergency department setting. However, neither biomarker discriminated between AKI and CKD. Additional biomarkers continue to be needed for improved specificity in the diagnosis of community-acquired AKI.

show abstract

“…The most used marker in clinical practice is endogenous and is serum creatinine. However, it does not comply to all of these last features [3] and it is indeed a poor marker for GFR, especially in specific population like obese, anorectic and transplanted patients [4,5]. In these specific patients and in clinical nephrological studies, a precise GFR measurement is needed.…”

Section: Introductionmentioning

confidence: 99%

Performance of iohexol determination in serum and urine by HPLC: Validation, risk and uncertainty assessment

Cavalier

Rozet

Dubois

et al. 2008

Clinica Chimica Acta

Self Cite

View full text Add to dashboard Cite

Background: Determination of glomerular filtration rate plays an important role in nephrological practice. Iohexol is a reference marker for glomerular filtration rate determination. It is available and safe. The aim of this study was to develop a simple, efficient and easy to use analytical method for the quantification of iohexol in serum and urine by high performance liquid chromatography and to thoroughly validate this method. Methods: The HPLC method was inspired from the method published by Krutzen. The e.noval software V2.0 (Arlenda, Liège, Belgium) was used to compute all validation results. Results: The validation results indicate that the method will give accurate and reliable results for serum values ranging from 12.95 to 1295 μg/ml and for urine values ranging from 86.0 to 4144 μg/ml. In routine practice, iohexol concentrations found in plasma after injection range from 40 to 600 μg/ml. The expected urinary values are much wider. One should not hesitate to dilute urine samples to fit with the validated range over 5000 μg/ml. Conclusion: This is the first time that a reference method for the determination of GFR is validated with such a rigorous and thorough protocol. Contrary to other GFR markers, iohexol is now strongly validated from an analytical point of view.

show abstract

Plasmatic cystatin C for the estimation of glomerular filtration rate in intensive care units

Cited by 83 publications

References 18 publications

Early Predictors of Acute Kidney Injury (AKI) in a Sample of Egyptian Full Term Neonates

Early Predictors of Acute Kidney Injury (AKI) in a Sample of Egyptian Full Term Neonates

Cystatin C as a Marker of Acute Kidney Injury in the Emergency Department

Performance of iohexol determination in serum and urine by HPLC: Validation, risk and uncertainty assessment

Contact Info

Product

Resources

About